Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention

BACKGROUND:Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize the definition of HBR, which was arbitrarily defined as a Bleeding Academic Research Consortium 3 or 5 bleeding ≥4% at 1-year. However, the prevalence and the expected bleeding eve...

Full description

Saved in:
Bibliographic Details
Published inCirculation. Cardiovascular interventions Vol. 12; no. 11; p. e008307
Main Authors Natsuaki, Masahiro, Morimoto, Takeshi, Shiomi, Hiroki, Yamaji, Kyohei, Watanabe, Hirotoshi, Shizuta, Satoshi, Kato, Takao, Ando, Kenji, Nakagawa, Yoshihisa, Furukawa, Yutaka, Tada, Tomohisa, Nagao, Kazuya, Kadota, Kazushige, Toyofuku, Mamoru, Kimura, Takeshi
Format Journal Article
LanguageEnglish
Published American Heart Association, Inc 01.11.2019
Online AccessGet full text

Cover

Loading…
Abstract BACKGROUND:Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize the definition of HBR, which was arbitrarily defined as a Bleeding Academic Research Consortium 3 or 5 bleeding ≥4% at 1-year. However, the prevalence and the expected bleeding event rate of HBR patients defined by ARC-HBR criteria are currently unknown in the real-world percutaneous coronary intervention practice. METHODS:We applied the ARC-HBR criteria in the CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) registry cohort-2, a multicenter registry that enrolled 13 058 consecutive patients who underwent their first percutaneous coronary intervention. The primary bleeding end point was defined as the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries moderate/severe bleeding. There were 5570 patients (43%) in the HBR group and 7488 patients in the no-HBR group. RESULTS:Cumulative incidence of the primary bleeding end point was much higher in the HBR group than in the no-HBR group (10.4% versus 3.4% at 1-year, and 18.9% versus 6.6% at 5-year, P<0.0001). Presence of each ARC-HBR major or even minor criterion, in isolation, with the exception of liver cirrhosis and prior ischemic stroke, was also associated with major bleeding risk higher than 4% at 1-year. Cumulative 5-year incidence of the primary bleeding end point got incrementally higher as the number of the ARC-HBR major criteria increased (≥3 majors49.9%, 2 majors30.6%, 1 major18.5%, ≥2 minors14.7%, and no-HBR6.6%, P<0.0001). CONCLUSIONS:ARC-HBR criteria successfully identified those patients with very HBR after percutaneous coronary intervention, who represented 43% of patients in this all-comers registry.
AbstractList BACKGROUNDRecently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize the definition of HBR, which was arbitrarily defined as a Bleeding Academic Research Consortium 3 or 5 bleeding ≥4% at 1-year. However, the prevalence and the expected bleeding event rate of HBR patients defined by ARC-HBR criteria are currently unknown in the real-world percutaneous coronary intervention practice. METHODSWe applied the ARC-HBR criteria in the CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) registry cohort-2, a multicenter registry that enrolled 13 058 consecutive patients who underwent their first percutaneous coronary intervention. The primary bleeding end point was defined as the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries moderate/severe bleeding. There were 5570 patients (43%) in the HBR group and 7488 patients in the no-HBR group. RESULTSCumulative incidence of the primary bleeding end point was much higher in the HBR group than in the no-HBR group (10.4% versus 3.4% at 1-year, and 18.9% versus 6.6% at 5-year, P<0.0001). Presence of each ARC-HBR major or even minor criterion, in isolation, with the exception of liver cirrhosis and prior ischemic stroke, was also associated with major bleeding risk higher than 4% at 1-year. Cumulative 5-year incidence of the primary bleeding end point got incrementally higher as the number of the ARC-HBR major criteria increased (≥3 majors: 49.9%, 2 majors: 30.6%, 1 major: 18.5%, ≥2 minors: 14.7%, and no-HBR: 6.6%, P<0.0001). CONCLUSIONSARC-HBR criteria successfully identified those patients with very HBR after percutaneous coronary intervention, who represented 43% of patients in this all-comers registry.
BACKGROUND:Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize the definition of HBR, which was arbitrarily defined as a Bleeding Academic Research Consortium 3 or 5 bleeding ≥4% at 1-year. However, the prevalence and the expected bleeding event rate of HBR patients defined by ARC-HBR criteria are currently unknown in the real-world percutaneous coronary intervention practice. METHODS:We applied the ARC-HBR criteria in the CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) registry cohort-2, a multicenter registry that enrolled 13 058 consecutive patients who underwent their first percutaneous coronary intervention. The primary bleeding end point was defined as the Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries moderate/severe bleeding. There were 5570 patients (43%) in the HBR group and 7488 patients in the no-HBR group. RESULTS:Cumulative incidence of the primary bleeding end point was much higher in the HBR group than in the no-HBR group (10.4% versus 3.4% at 1-year, and 18.9% versus 6.6% at 5-year, P<0.0001). Presence of each ARC-HBR major or even minor criterion, in isolation, with the exception of liver cirrhosis and prior ischemic stroke, was also associated with major bleeding risk higher than 4% at 1-year. Cumulative 5-year incidence of the primary bleeding end point got incrementally higher as the number of the ARC-HBR major criteria increased (≥3 majors49.9%, 2 majors30.6%, 1 major18.5%, ≥2 minors14.7%, and no-HBR6.6%, P<0.0001). CONCLUSIONS:ARC-HBR criteria successfully identified those patients with very HBR after percutaneous coronary intervention, who represented 43% of patients in this all-comers registry.
Author Natsuaki, Masahiro
Tada, Tomohisa
Toyofuku, Mamoru
Yamaji, Kyohei
Watanabe, Hirotoshi
Kadota, Kazushige
Nakagawa, Yoshihisa
Nagao, Kazuya
Furukawa, Yutaka
Shiomi, Hiroki
Kato, Takao
Kimura, Takeshi
Morimoto, Takeshi
Shizuta, Satoshi
Ando, Kenji
AuthorAffiliation Department of Cardiovascular Medicine, Saga University, Japan (M.N.). Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan (T.M.). Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (H.S., H.W., S.S., T. Kato, T. Kimura). Division of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan (K.Y., K.A.). Department of Cardiovascular Medicine, Shiga University of Medical Science Hospital, Otsu, Japan (Y.N.). Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Japan (Y.F.). Division of Cardiology, Shizuoka General Hospital, Japan (T.T.). Department of Cardiovascular Center, Osaka Red Cross Hospital, Japan (K.N.). Division of Cardiology, Kurashiki Central Hospital, Japan (K.K.). Division of Cardiology, Wakayama Red Cross Hospital, Wakayama, Japan (M.T.)
AuthorAffiliation_xml – name: Department of Cardiovascular Medicine, Saga University, Japan (M.N.). Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan (T.M.). Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (H.S., H.W., S.S., T. Kato, T. Kimura). Division of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan (K.Y., K.A.). Department of Cardiovascular Medicine, Shiga University of Medical Science Hospital, Otsu, Japan (Y.N.). Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Japan (Y.F.). Division of Cardiology, Shizuoka General Hospital, Japan (T.T.). Department of Cardiovascular Center, Osaka Red Cross Hospital, Japan (K.N.). Division of Cardiology, Kurashiki Central Hospital, Japan (K.K.). Division of Cardiology, Wakayama Red Cross Hospital, Wakayama, Japan (M.T.)
Author_xml – sequence: 1
  givenname: Masahiro
  surname: Natsuaki
  fullname: Natsuaki, Masahiro
  organization: Department of Cardiovascular Medicine, Saga University, Japan (M.N.). Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan (T.M.). Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan (H.S., H.W., S.S., T. Kato, T. Kimura). Division of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan (K.Y., K.A.). Department of Cardiovascular Medicine, Shiga University of Medical Science Hospital, Otsu, Japan (Y.N.). Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Japan (Y.F.). Division of Cardiology, Shizuoka General Hospital, Japan (T.T.). Department of Cardiovascular Center, Osaka Red Cross Hospital, Japan (K.N.). Division of Cardiology, Kurashiki Central Hospital, Japan (K.K.). Division of Cardiology, Wakayama Red Cross Hospital, Wakayama, Japan (M.T.)
– sequence: 2
  givenname: Takeshi
  surname: Morimoto
  fullname: Morimoto, Takeshi
– sequence: 3
  givenname: Hiroki
  surname: Shiomi
  fullname: Shiomi, Hiroki
– sequence: 4
  givenname: Kyohei
  surname: Yamaji
  fullname: Yamaji, Kyohei
– sequence: 5
  givenname: Hirotoshi
  surname: Watanabe
  fullname: Watanabe, Hirotoshi
– sequence: 6
  givenname: Satoshi
  surname: Shizuta
  fullname: Shizuta, Satoshi
– sequence: 7
  givenname: Takao
  surname: Kato
  fullname: Kato, Takao
– sequence: 8
  givenname: Kenji
  surname: Ando
  fullname: Ando, Kenji
– sequence: 9
  givenname: Yoshihisa
  surname: Nakagawa
  fullname: Nakagawa, Yoshihisa
– sequence: 10
  givenname: Yutaka
  surname: Furukawa
  fullname: Furukawa, Yutaka
– sequence: 11
  givenname: Tomohisa
  surname: Tada
  fullname: Tada, Tomohisa
– sequence: 12
  givenname: Kazuya
  surname: Nagao
  fullname: Nagao, Kazuya
– sequence: 13
  givenname: Kazushige
  surname: Kadota
  fullname: Kadota, Kazushige
– sequence: 14
  givenname: Mamoru
  surname: Toyofuku
  fullname: Toyofuku, Mamoru
– sequence: 15
  givenname: Takeshi
  surname: Kimura
  fullname: Kimura, Takeshi
BookMark eNplkcFu3CAQhq0qlZqkfQcOPfTiFAzGIPWytTaNpWhTbbe9IpYdr2kwbMFu1GfIS4eVq156QIP-mf9j0H9VXPjgoSjeE3xDCCcf227bdpvdevtjvdl1D5tvWZY3GAuKm1fFJZGMlA2n1cW_O8NviquUfmKcZV5dFs-r08lZoycbPAo9mgZAK6MPMFqDtpBARzOgNvgU4mTnEd3Z44A-O4CD9Ue0tekRtdFOEK1G1iPt0cq5sg0jxJQBR5um-OdM_grRzJP2EOaUgTF4nRudz9bf4M_vvy1e99olePe3Xhffb9e79q68f_jStav70jBe81L0daOF2Au8N72uRc8M7QkwSRjfgwTOq8ow2AOpRMMPkor6UOsaQIDkRjT0uviwcE8x_JohTWq0yYBzy3KqooRmiGzOo5-WURNDShF6dYp2zIsrgtU5A_VfBlmWaskg29lifwou_zM9uvkJohpAu2lQmFDaMFmXFSaSEIxxmU9O5gX70JDz
CitedBy_id crossref_primary_10_3389_fcvm_2022_878270
crossref_primary_10_1016_j_ijcard_2021_11_015
crossref_primary_10_1253_circj_CJ_21_0120
crossref_primary_10_1016_j_rec_2021_11_005
crossref_primary_10_1253_circj_CJ_21_1049
crossref_primary_10_1002_ccd_29588
crossref_primary_10_1016_j_jjcc_2020_03_001
crossref_primary_10_1016_j_jjcc_2021_05_016
crossref_primary_10_1007_s00380_021_01804_3
crossref_primary_10_1253_circj_CJ_19_1109
crossref_primary_10_3390_jcm11040988
crossref_primary_10_1016_j_jacasi_2022_11_012
crossref_primary_10_4244_EIJV16I5A64
crossref_primary_10_1016_j_jacc_2020_04_024
crossref_primary_10_1093_eurheartj_ehaa671
crossref_primary_10_1253_circj_CJ_21_0526
crossref_primary_10_4244_EIJ_D_20_00749
crossref_primary_10_1161_CIRCINTERVENTIONS_121_010591
crossref_primary_10_1016_j_recesp_2021_10_013
crossref_primary_10_4244_EIJ_D_20_00345
crossref_primary_10_1253_circj_CJ_19_1117
crossref_primary_10_1007_s00380_021_01836_9
crossref_primary_10_1253_circj_CJ_22_0826
crossref_primary_10_1016_j_ijcard_2023_131565
crossref_primary_10_3346_jkms_2021_36_e268
crossref_primary_10_1016_j_thromres_2022_04_004
crossref_primary_10_1016_j_jacc_2020_06_085
crossref_primary_10_4244_EIJ_D_22_00475
crossref_primary_10_1007_s00380_021_01813_2
crossref_primary_10_4244_EIJV16I14A202
crossref_primary_10_5551_jat_62999
crossref_primary_10_1007_s12928_024_00999_2
crossref_primary_10_1007_s12928_021_00805_3
crossref_primary_10_1177_2048872620921596
crossref_primary_10_1016_j_jacasi_2021_08_010
crossref_primary_10_1093_eurheartj_ehaa699
crossref_primary_10_1253_circj_CJ_21_0192
crossref_primary_10_1253_circrep_CR_22_0023
crossref_primary_10_1371_journal_pone_0261371
crossref_primary_10_3390_jcm11051324
crossref_primary_10_4070_kcj_2021_0321
crossref_primary_10_1177_00033197221135739
crossref_primary_10_1016_j_numecd_2022_01_016
crossref_primary_10_1253_circj_CJ_20_0806
crossref_primary_10_3390_jcm13061730
crossref_primary_10_1253_circj_CJ_21_0901
crossref_primary_10_1016_j_rec_2021_03_006
crossref_primary_10_1161_CIRCINTERVENTIONS_120_010392
crossref_primary_10_1161_CIRCINTERVENTIONS_119_008569
crossref_primary_10_1253_circj_CJ_21_0620
crossref_primary_10_1253_circj_CJ_20_0253
crossref_primary_10_3389_fcvm_2021_589426
crossref_primary_10_1016_j_ijcard_2020_10_015
crossref_primary_10_1016_j_jacasi_2021_12_005
crossref_primary_10_1007_s00380_024_02428_z
crossref_primary_10_1016_j_ejim_2024_04_016
crossref_primary_10_3389_fcvm_2021_620354
crossref_primary_10_5551_jat_64242
crossref_primary_10_3390_jcm9061963
crossref_primary_10_1038_s41598_023_39213_3
crossref_primary_10_1016_j_jjcc_2020_12_004
crossref_primary_10_1007_s12928_019_00633_6
crossref_primary_10_1253_circrep_CR_23_0087
crossref_primary_10_1253_circj_CJ_20_0836
crossref_primary_10_3390_jcm9093039
crossref_primary_10_2169_internalmedicine_6549_20
crossref_primary_10_1016_j_recesp_2021_03_012
crossref_primary_10_1136_bmjopen_2023_077852
crossref_primary_10_1007_s12928_022_00877_9
crossref_primary_10_1253_circj_CJ_20_0786
crossref_primary_10_1016_j_carrev_2024_04_022
crossref_primary_10_1016_j_ahjo_2022_100227
crossref_primary_10_1016_j_jjcc_2023_04_012
crossref_primary_10_1007_s40256_021_00468_8
crossref_primary_10_1253_circj_CJ_21_0686
crossref_primary_10_1007_s12928_023_00920_3
crossref_primary_10_1253_circj_CJ_20_0395
crossref_primary_10_1177_15266028231176953
crossref_primary_10_1016_j_ccl_2020_06_002
crossref_primary_10_1016_j_ahj_2020_09_019
crossref_primary_10_1016_j_ijcard_2020_10_073
crossref_primary_10_5551_jat_RV17066
crossref_primary_10_4244_EIJ_D_20_00052
crossref_primary_10_3389_fcvm_2022_774123
crossref_primary_10_1001_jamacardio_2021_5244
crossref_primary_10_1080_09537104_2021_1981847
crossref_primary_10_1253_circj_CJ_21_0016
crossref_primary_10_1093_ehjopen_oeab036
crossref_primary_10_1161_CIRCINTERVENTIONS_121_011299
crossref_primary_10_1016_j_hjc_2022_04_008
crossref_primary_10_1001_jamacardio_2020_6814
crossref_primary_10_7759_cureus_58302
crossref_primary_10_1016_j_amjcard_2021_10_043
crossref_primary_10_1016_j_jacasi_2022_09_011
crossref_primary_10_1016_j_jjcc_2022_02_018
crossref_primary_10_1038_s41569_021_00598_1
crossref_primary_10_1055_s_0040_1712449
crossref_primary_10_1016_j_jjcc_2023_01_003
Cites_doi 10.1056/NEJMoa1503943
10.1016/j.jcin.2015.11.015
10.1001/jama.2016.3775
10.1161/JAHA.118.008708
10.1001/jama.2019.8145
10.1056/NEJM199309023291001
10.1016/j.jacc.2013.08.1651
10.1016/j.jacc.2018.11.048
10.1161/CIRCULATIONAHA.119.040167
10.1093/eurheartj/ehx419
10.1253/circj.CJ-19-0133
10.1371/journal.pone.0174502
10.1161/CIRCULATIONAHA.112.104059
10.1016/j.jacc.2013.04.045
10.1016/S0140-6736(17)32713-7
10.1016/j.jacc.2016.02.064
10.1016/S0140-6736(17)30397-5
10.1007/s12928-011-0065-0
10.1056/NEJMoa1409312
ContentType Journal Article
Copyright 2019 American Heart Association, Inc.
Copyright_xml – notice: 2019 American Heart Association, Inc.
CorporateAuthor on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators
CorporateAuthor_xml – sequence: 0
  name: on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators
DBID AAYXX
CITATION
7X8
DOI 10.1161/CIRCINTERVENTIONS.119.008307
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

DeliveryMethod fulltext_linktorsrc
EISSN 1941-7632
EndPage e008307
ExternalDocumentID 10_1161_CIRCINTERVENTIONS_119_008307
01337495-201911000-00006
GroupedDBID -
.XZ
.Z2
0R
53G
AAPBV
AARTV
ABBUW
ABXVJ
ABZAD
ACDDN
ACEWG
ACWDW
ACWRI
ACXNZ
ADACO
ADBBV
ADNKB
AFUWQ
AHULI
AHVBC
AJIOK
AJNYG
ALMA_UNASSIGNED_HOLDINGS
AMJPA
ASCII
BAWUL
BQLVK
C45
CS3
DIK
DUNZO
E.X
E3Z
EBS
EJD
EX3
F5P
FL-
H13
HZ
IN
IN~
JF7
KD2
KQ8
KQB
L-C
O9-
OHASI
OK1
OLW
OPUJH
OUVQU
OVD
OVDNE
OXXIT
RAH
RHF
RIG
RLZ
S4S
V2I
W2D
WOW
XZ
Z2
---
0R~
18M
5VS
6J9
AAAAV
AAHPQ
AAIQE
AAJCS
AASCR
AAYXX
ABASU
ABDIG
ABJNI
ABVCZ
ACGFS
ACILI
ACXJB
ADGGA
ADHPY
AEBDS
AEETU
AFDTB
AFEXH
AGINI
AHQNM
AHRYX
AINUH
AJNWD
AJZMW
ALMTX
AMKUR
AMNEI
AOHHW
CITATION
DIWNM
EEVPB
FCALG
GNXGY
GQDEL
HLJTE
HZ~
IKREB
IPNFZ
ODMTH
ODZKP
OHYEH
P6G
TEORI
TR2
TSPGW
W3M
W8F
ZZMQN
7X8
ID FETCH-LOGICAL-c4656-8f57a88b80bcfa58f4c3f1e49146be9e6622c4ebe12876d9385d5a5ee8e96c873
ISSN 1941-7640
IngestDate Fri Aug 16 02:04:18 EDT 2024
Fri Dec 06 03:10:11 EST 2024
Thu Aug 13 19:50:32 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4656-8f57a88b80bcfa58f4c3f1e49146be9e6622c4ebe12876d9385d5a5ee8e96c873
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.119.008307
PQID 2313662977
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2313662977
crossref_primary_10_1161_CIRCINTERVENTIONS_119_008307
wolterskluwer_health_01337495-201911000-00006
ProviderPackageCode ACEWG
L-C
C45
.Z2
AARTV
ASCII
ABZAD
ABBUW
OUVQU
ADNKB
OLW
KQB
ACDDN
ACWRI
OHASI
AHVBC
AJNYG
FL-
AJIOK
OPUJH
V2I
E.X
.XZ
ACXNZ
S4S
DUNZO
OVDNE
AMJPA
ABXVJ
IN~
KD2
OXXIT
JF7
ACWDW
OVD
AHULI
PublicationCentury 2000
PublicationDate 2019-November
2019-11-00
20191101
PublicationDateYYYYMMDD 2019-11-01
PublicationDate_xml – month: 11
  year: 2019
  text: 2019-November
PublicationDecade 2010
PublicationTitle Circulation. Cardiovascular interventions
PublicationYear 2019
Publisher American Heart Association, Inc
Publisher_xml – name: American Heart Association, Inc
References e_1_3_5_17_2
e_1_3_5_16_2
e_1_3_5_15_2
e_1_3_5_14_2
e_1_3_5_12_2
e_1_3_5_13_2
e_1_3_5_10_2
e_1_3_5_11_2
e_1_3_5_19_2
e_1_3_5_18_2
e_1_3_5_2_2
e_1_3_5_8_2
e_1_3_5_20_2
e_1_3_5_7_2
e_1_3_5_9_2
e_1_3_5_4_2
e_1_3_5_3_2
e_1_3_5_6_2
e_1_3_5_5_2
References_xml – ident: e_1_3_5_5_2
  doi: 10.1056/NEJMoa1503943
– ident: e_1_3_5_6_2
  doi: 10.1016/j.jcin.2015.11.015
– ident: e_1_3_5_9_2
  doi: 10.1001/jama.2016.3775
– ident: e_1_3_5_11_2
  doi: 10.1161/JAHA.118.008708
– ident: e_1_3_5_18_2
  doi: 10.1001/jama.2019.8145
– ident: e_1_3_5_14_2
  doi: 10.1056/NEJM199309023291001
– ident: e_1_3_5_17_2
  doi: 10.1016/j.jacc.2013.08.1651
– ident: e_1_3_5_19_2
  doi: 10.1016/j.jacc.2018.11.048
– ident: e_1_3_5_12_2
  doi: 10.1161/CIRCULATIONAHA.119.040167
– ident: e_1_3_5_3_2
  doi: 10.1093/eurheartj/ehx419
– ident: e_1_3_5_4_2
  doi: 10.1253/circj.CJ-19-0133
– ident: e_1_3_5_2_2
  doi: 10.1371/journal.pone.0174502
– ident: e_1_3_5_15_2
  doi: 10.1161/CIRCULATIONAHA.112.104059
– ident: e_1_3_5_16_2
  doi: 10.1016/j.jacc.2013.04.045
– ident: e_1_3_5_7_2
  doi: 10.1016/S0140-6736(17)32713-7
– ident: e_1_3_5_10_2
  doi: 10.1016/j.jacc.2016.02.064
– ident: e_1_3_5_8_2
  doi: 10.1016/S0140-6736(17)30397-5
– ident: e_1_3_5_13_2
  doi: 10.1007/s12928-011-0065-0
– ident: e_1_3_5_20_2
  doi: 10.1056/NEJMoa1409312
SSID ssj0063262
Score 2.5841796
Snippet BACKGROUND:Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize the definition of HBR, which was...
BACKGROUNDRecently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) has been proposed to standardize the definition of HBR, which was...
SourceID proquest
crossref
wolterskluwer
SourceType Aggregation Database
Publisher
StartPage e008307
Title Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention
URI http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=01337495-201911000-00006
https://search.proquest.com/docview/2313662977
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaqRUJICIEAUV4y0t5WKc07PpayqAVtD1UXLafIcR2abZugPoTgL_CXOTBjx4mrAmK5RJXTOI_54nxjfzNDyKnHZTBnou-I3E2cIIq4A2b2nVwwL-fMD-dqRfdiEo0ug_dX4VWn89NSLe13WU98_21cyf9YFdrArhglewPLNp1CA_wG-8IWLAzbf7LxoF19Nmv9jd7dSOpUSU7g2MV-rUQdZ29W-oN1NkVVOZY6wEvFeQ941QerlQNDBEb1TuVnVQlOqeTkRuyBRkoUzA4x6QGK7caWXtImucNiI-qqYD1UlBwIXq1jGjo_4bvtnusC2hd8yxfFpmqQUG0QTmpGd8aXcrsomlmhRVGtddVtOGDZtH_ia36tVQrfqoUs7JkNl9Uhfg0WzZLVCB7XzobrkUzUZYHrxJFO_NSTdpt_ONZ7NqZda-SWSEZ1Ad6aCFgtx9-ZCL8zw_F0qDIXfzyfqKBv2IHpT9uODjJ5A9v2Y3BIHbxZTNWnYvoxX_wtTOOIlR_ejj8YHgFXrsrhNvd2m5zWp379txMfEqzWa7r7tUL9xXapwi8sEjW7T-7V3g8daCg_IB1ZPiQ_LBjTKqcAY2pgTA2MaQtjijCmBsYUYUwNjGlRUl7SFsbUwBh7tmFMDYypDeNH5PLd-Ww4cuoaIY7ATH9OkocxT5Is6Wci52GSB8LPXRkwYACZZDKKPE8EMFIBD4ujOfOTcB7yUMpEskgksf-YnJRVKZ8QGubgLQlX4Nx-wLHbvjsHeh3nCQv6XtYloXmw6RedCiZVLnTkpkcGgWaWaoN0yStjhRTGblyQ0zeagm_lwwWCC9YlzoF5Uh0Fnf4JMk9v-P9n5E77hj0nJ7vNXr4ANr3LXirQ_QJIecoE
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Application+of+the+Academic+Research+Consortium+High+Bleeding+Risk+Criteria+in+an+All-Comers+Registry+of+Percutaneous+Coronary+Intervention&rft.jtitle=Circulation.+Cardiovascular+interventions&rft.au=Natsuaki%2C+Masahiro&rft.au=Morimoto%2C+Takeshi&rft.au=Shiomi%2C+Hiroki&rft.au=Yamaji%2C+Kyohei&rft.date=2019-11-01&rft.pub=American+Heart+Association%2C+Inc&rft.issn=1941-7640&rft.eissn=1941-7632&rft.volume=12&rft.issue=11&rft.spage=e008307&rft.epage=e008307&rft_id=info:doi/10.1161%2FCIRCINTERVENTIONS.119.008307&rft.externalDocID=01337495-201911000-00006
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-7640&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-7640&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-7640&client=summon